157 related articles for article (PubMed ID: 31877199)
1. Impact of the change in the antitubercular regimen from three to four drugs on cure and frequency of adverse reactions in tuberculosis patients from Brazil: A retrospective cohort study.
Arriaga MB; Torres NMC; Araujo NCN; Caldas SCC; Andrade BB; Netto EM
PLoS One; 2019; 14(12):e0227101. PubMed ID: 31877199
[TBL] [Abstract][Full Text] [Related]
2. Incidence and outcomes of adverse drug reactions to first-line anti-tuberculosis drugs and their effects on the quality of life: A multicenter prospective cohort study.
Choi H; Park HA; Hyun IG; Kim JH; Hwang YI; Jang SH; Sim YS; Shin TR; Ko Y; Ban GY; Hong JY; Lee CY; Lee MG; Choi JH
Pharmacoepidemiol Drug Saf; 2022 Nov; 31(11):1153-1163. PubMed ID: 35909258
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of adverse reactions induced by anti-tuberculosis drugs among hospitalized patients in Wuhan, China: A retrospective study.
Shi C; Yang B; Yang J; Song W; Chen Y; Zhang S; Zhan H; Xiong Y; Rong P; Luo Y; Yang J
Medicine (Baltimore); 2024 May; 103(20):e38273. PubMed ID: 38758847
[TBL] [Abstract][Full Text] [Related]
4. Adverse reactions due to directly observed treatment strategy therapy in Chinese tuberculosis patients: a prospective study.
Lv X; Tang S; Xia Y; Wang X; Yuan Y; Hu D; Liu F; Wu S; Zhang Y; Yang Z; Tu D; Chen Y; Deng P; Ma Y; Chen R; Zhan S
PLoS One; 2013; 8(6):e65037. PubMed ID: 23750225
[TBL] [Abstract][Full Text] [Related]
5. Adverse events during treatment of drug-resistant tuberculosis: a comparison between patients with or without human immunodeficiency virus co-infection.
Sagwa E; Ruswa N; Musasa JP; Mantel-Teeuwisse AK
Drug Saf; 2013 Nov; 36(11):1087-96. PubMed ID: 23917883
[TBL] [Abstract][Full Text] [Related]
6. Impact of adverse drug reactions on the outcomes of tuberculosis treatment.
Sant Anna FM; Araújo-Pereira M; Schmaltz CAS; Arriaga MB; Andrade BB; Rolla VC
PLoS One; 2023; 18(2):e0269765. PubMed ID: 36749743
[TBL] [Abstract][Full Text] [Related]
7. Estimated rates of recurrence, cure, and treatment abandonment in patients with pulmonary tuberculosis treated with a -four-drug fixed-dose combination regimen at a tertiary health care facility in the city of Rio de Janeiro, Brazil.
Silva VDD; Mello FCQ; Figueiredo SCA
J Bras Pneumol; 2017; 43(2):113-120. PubMed ID: 28538778
[TBL] [Abstract][Full Text] [Related]
8. Genetic interaction between NAT2, GSTM1, GSTT1, CYP2E1, and environmental factors is associated with adverse reactions to anti-tuberculosis drugs.
Costa GN; Magno LA; Santana CV; Konstantinovas C; Saito ST; Machado M; Di Pietro G; Bastos-Rodrigues L; Miranda DM; De Marco LA; Romano-Silva MA; Rios-Santos F
Mol Diagn Ther; 2012 Aug; 16(4):241-50. PubMed ID: 22788240
[TBL] [Abstract][Full Text] [Related]
9. Incidence of adverse reactions caused by first-line anti-tuberculosis drugs and treatment outcome of pulmonary tuberculosis patients in Morocco.
El Hamdouni M; Ahid S; Bourkadi JE; Benamor J; Hassar M; Cherrah Y
Infection; 2020 Feb; 48(1):43-50. PubMed ID: 31165445
[TBL] [Abstract][Full Text] [Related]
10. Clinical treatment outcomes of tuberculosis treated with the basic regimen recommended by the Brazilian National Ministry of Health using fixed-dose combination tablets in the greater metropolitan area of Goiânia, Brazil.
Ferreira AC; Silva Júnior JL; Conde MB; Rabahi MF
J Bras Pneumol; 2013; 39(1):76-83. PubMed ID: 23503489
[TBL] [Abstract][Full Text] [Related]
11. Putting in harm to cure: Drug related adverse events do not affect outcome of patients receiving treatment for multidrug-resistant Tuberculosis. Experience from a tertiary hospital in Italy.
Gualano G; Mencarini P; Musso M; Mosti S; Santangelo L; Murachelli S; Cannas A; Di Caro A; Navarra A; Goletti D; Girardi E; Palmieri F
PLoS One; 2019; 14(2):e0212948. PubMed ID: 30817779
[TBL] [Abstract][Full Text] [Related]
12. Substantially Higher and Earlier Occurrence of Anti-Tuberculosis Drug-Related Adverse Reactions in HIV Coinfected Tuberculosis Patients: A Matched-Cohort Study.
Matono T; Nishijima T; Teruya K; Morino E; Takasaki J; Gatanaga H; Kikuchi Y; Kaku M; Oka S
AIDS Patient Care STDS; 2017 Nov; 31(11):455-462. PubMed ID: 29087745
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of 3 Months of Once-Weekly Rifapentine and Isoniazid for Latent Tuberculosis Infection.
Walker RE; Bass S; Srinivas P; Miranda C; Johnson L; Pallotta AM
Ann Pharmacother; 2020 May; 54(5):457-463. PubMed ID: 31729245
[No Abstract] [Full Text] [Related]
14. Anti-tuberculosis drugs adverse reactions: a review of the Iranian literature.
Kargar M; Mansouri A; Hadjibabaie M; Javadi M; Radfar M; Gholami K
Expert Opin Drug Saf; 2014 Jul; 13(7):875-91. PubMed ID: 24935479
[TBL] [Abstract][Full Text] [Related]
15. Design of the anti-tuberculosis drugs induced adverse reactions in China National Tuberculosis Prevention and Control Scheme Study (ADACS).
Xia YY; Hu DY; Liu FY; Wang XM; Yuan YL; Tu DH; Chen YX; Zhou L; Zhu LZ; Gao WW; Wang HY; Chen da F; Yang L; He PP; Li XT; He YJ; Sun F; Zhan SY
BMC Public Health; 2010 May; 10():267. PubMed ID: 20492672
[TBL] [Abstract][Full Text] [Related]
16. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
[TBL] [Abstract][Full Text] [Related]
17. Prediction Models for Adverse Drug Reactions During Tuberculosis Treatment in Brazil.
Ridolfi F; Amorim G; Peetluk LS; Haas DW; Staats C; Araújo-Pereira M; Cordeiro-Santos M; Kritski AL; Figueiredo MC; Andrade BB; Rolla VC; Sterling TR;
J Infect Dis; 2024 Mar; 229(3):813-823. PubMed ID: 38262629
[TBL] [Abstract][Full Text] [Related]
18. Adverse reactions of anti-tuberculosis drugs in hospitalized patients: incidence, severity and risk factors.
Javadi MR; Shalviri G; Gholami K; Salamzadeh J; Maghooli G; Mirsaeedi SM
Pharmacoepidemiol Drug Saf; 2007 Oct; 16(10):1104-10. PubMed ID: 17823987
[TBL] [Abstract][Full Text] [Related]
19. Prevalence and Risk Factors Associated with Adverse Drug Reactions among Previously Treated Tuberculosis Patients in China.
Han XQ; Pang Y; Ma Y; Liu YH; Guo R; Shu W; Huang XR; Ge QP; DU J; Gao WW
Biomed Environ Sci; 2017 Feb; 30(2):139-142. PubMed ID: 28292352
[TBL] [Abstract][Full Text] [Related]
20. Hyperglycemia during tuberculosis treatment increases morbidity and mortality in a contemporary cohort of HIV-infected patients in Rio de Janeiro, Brazil.
Moreira J; Castro R; Lamas C; Ribeiro S; Grinsztejn B; Veloso VG
Int J Infect Dis; 2018 Apr; 69():11-19. PubMed ID: 29253707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
